Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Blockade of the PDGFR family together with SRC leads to diminished proliferation of colorectal cancer cells.

Kaulfuß S, Seemann H, Kampe R, Meyer J, Dressel R, König B, Scharf JG, Burfeind P.

Oncotarget. 2013 Jul;4(7):1037-49.

2.

The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer.

Baker AM, Cox TR, Bird D, Lang G, Murray GI, Sun XF, Southall SM, Wilson JR, Erler JT.

J Natl Cancer Inst. 2011 Mar 2;103(5):407-24. doi: 10.1093/jnci/djq569. Epub 2011 Jan 31.

PMID:
21282564
3.

Ki11502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo.

Nishioka C, Ikezoe T, Yang J, Miwa A, Tasaka T, Kuwayama Y, Togitani K, Koeffler HP, Yokoyama A.

Blood. 2008 May 15;111(10):5086-92. doi: 10.1182/blood-2007-06-098079. Epub 2008 Feb 28.

4.

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.

Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL.

Oncogene. 2011 Feb 3;30(5):561-74. doi: 10.1038/onc.2010.430. Epub 2010 Oct 18.

5.

Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.

Dong Y, Jia L, Wang X, Tan X, Xu J, Deng Z, Jiang T, Rainov NG, Li B, Ren H.

Int J Oncol. 2011 Feb;38(2):555-69. doi: 10.3892/ijo.2010.861. Epub 2010 Dec 6.

PMID:
21152856
6.

[Abnormal expression of APRIL in colorectal cancer cells promotes tumor growth and metastasis].

Wang GH, Lu MH, Wang JC, Wang F, Ding WF, Wang YG, Ju SQ, Wang HM.

Zhonghua Zhong Liu Za Zhi. 2013 Apr;35(4):249-55. doi: 10.3760/cma.j.issn.0253-3766.2013.04.003. Chinese.

PMID:
23985251
7.
8.

Role of Src tyrosine kinases in experimental pulmonary hypertension.

Pullamsetti SS, Berghausen EM, Dabral S, Tretyn A, Butrous E, Savai R, Butrous G, Dahal BK, Brandes RP, Ghofrani HA, Weissmann N, Grimminger F, Seeger W, Rosenkranz S, Schermuly RT.

Arterioscler Thromb Vasc Biol. 2012 Jun;32(6):1354-65. doi: 10.1161/ATVBAHA.112.248500. Epub 2012 Apr 19.

9.

Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.

Ruan J, Luo M, Wang C, Fan L, Yang SN, Cardenas M, Geng H, Leonard JP, Melnick A, Cerchietti L, Hajjar KA.

Blood. 2013 Jun 27;121(26):5192-202. doi: 10.1182/blood-2013-03-490763. Epub 2013 Apr 30.

10.

Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib.

Coluccia AM, Cirulli T, Neri P, Mangieri D, Colanardi MC, Gnoni A, Di Renzo N, Dammacco F, Tassone P, Ribatti D, Gambacorti-Passerini C, Vacca A.

Blood. 2008 Aug 15;112(4):1346-56. doi: 10.1182/blood-2007-10-116590. Epub 2008 Jun 4.

11.

SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling.

Coluccia AM, Benati D, Dekhil H, De Filippo A, Lan C, Gambacorti-Passerini C.

Cancer Res. 2006 Feb 15;66(4):2279-86.

12.

mTOR signaling pathway is a target for the treatment of colorectal cancer.

Zhang YJ, Dai Q, Sun DF, Xiong H, Tian XQ, Gao FH, Xu MH, Chen GQ, Han ZG, Fang JY.

Ann Surg Oncol. 2009 Sep;16(9):2617-28. doi: 10.1245/s10434-009-0555-9. Epub 2009 Jun 11.

PMID:
19517193
13.
14.

The platelet-derived growth factor receptor-beta phosphorylates and activates G protein-coupled receptor kinase-2. A mechanism for feedback inhibition.

Wu JH, Goswami R, Kim LK, Miller WE, Peppel K, Freedman NJ.

J Biol Chem. 2005 Sep 2;280(35):31027-35. Epub 2005 Jul 1.

15.

Characterisation of Ki11502 as a potent inhibitor of PDGF beta receptor-mediated proteoglycan synthesis in vascular smooth muscle cells.

Getachew R, Ballinger ML, Burch ML, Little PJ, Osman N.

Eur J Pharmacol. 2010 Jan 25;626(2-3):186-92. doi: 10.1016/j.ejphar.2009.09.066. Epub 2009 Oct 8.

PMID:
19818754
16.
17.

Inhibition of platelet-derived growth factor receptor tyrosine kinase and downstream signaling pathways by Compound C.

Kwon HJ, Kim GE, Lee YT, Jeong MS, Kang I, Yang D, Yeo EJ.

Cell Signal. 2013 Apr;25(4):883-97. doi: 10.1016/j.cellsig.2012.12.016. Epub 2012 Dec 28.

PMID:
23277201
18.

A-kinase anchor protein 4 (AKAP4) a promising therapeutic target of colorectal cancer.

Jagadish N, Parashar D, Gupta N, Agarwal S, Purohit S, Kumar V, Sharma A, Fatima R, Topno AP, Shaha C, Suri A.

J Exp Clin Cancer Res. 2015 Nov 21;34:142. doi: 10.1186/s13046-015-0258-y.

19.

PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome.

Estevez-Garcia P, Castaño A, Martin AC, Lopez-Rios F, Iglesias J, Muñoz-Galván S, Lopez-Calderero I, Molina-Pinelo S, Pastor MD, Carnero A, Paz-Ares L, Garcia-Carbonero R.

BMC Cancer. 2012 Nov 12;12:514. doi: 10.1186/1471-2407-12-514.

20.

Global phosphotyrosine proteomics identifies PKCδ as a marker of responsiveness to Src inhibition in colorectal cancer.

McKinley ET, Liu H, McDonald WH, Luo W, Zhao P, Coffey RJ, Hanks SK, Manning HC.

PLoS One. 2013 Nov 8;8(11):e80207. doi: 10.1371/journal.pone.0080207. eCollection 2013.

Supplemental Content

Support Center